Vaborem 1 g/1 g powder for concentrate for solution for infusion

DRUG2 trials

Sponsors

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla, Menarini Ricerche S.p.A.

Conditions

Bacteriemia producida por P. aeruginosa.Suspected or confirmed Gram negative infections

Phase 2

An Open-label, Multicentre, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VaboremⓇ (Meropenem-Vaborbactam) in Paediatric Population with suspected or confirmed Gram negative infections, including but not restricted to Complicated Urinary Tract Infections.

RecruitingCTIS2024-514656-32-00

Menarini Ricerche S.p.A.Suspected or confirmed Gram negative infections

Start: 2025-01-23Target: 44Updated: 2025-09-12

Phase 4

Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.

Not yet recruitingCTIS2023-508441-41-00

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaBacteriemia producida por P. aeruginosa.

Target: 306Updated: 2025-07-25